The Top LineThe Top Line

November 11, 2022

View descriptionShare

This week on "The Top Line," we'll share highlights from the Cell & Gene Therapy Forum. Lack of access and multimillion-dollar costs have stirred debate over the appropriate price of potentially lifesaving cell and gene therapies. Fierce’s Max Bayer spoke with a panel of stakeholders at the forum. They discussed the state of play for cell and gene therapies and how they can become a genuine game changer for the many, not the few. We also talk with executives from Poseida Therapeutics and AviadoBio. 

To learn more about topics in this episode:

"The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

  • Facebook
  • Twitter
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

  1. The Top Line

    75 clip(s)

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fie 
Social links
Follow podcast
Recent clips
Browse 76 clip(s)